• Sphingosine-1-phosphate: S1P Signaling Guide

  2026-08-24

  Sphingosine-1-phosphate (S1P) is an endogenous bioactive lipid that links GPCR signaling with cell proliferation and survival signaling, vascular maturation, and apoptosis. Its effects depend on receptor subtype and biological context, as shown by S1PR1-associated vascular signaling and S1PR3-associated neuronal apoptosis after experimental intracerebral hemorrhage.

• Bafilomycin C1 in High-Content Phenotypic Screens

  2026-08-24

  Bafilomycin C1 is a vacuolar H+-ATPases inhibitor that can do more than block autophagic flux. This article presents a mechanistic framework for using lysosomal perturbation to interpret high-content and deep-learning phenotypic assays, including iPSC-cardiomyocyte models.

• Dye Models for Small Tissue Biopsies in Pathology

  2026-08-23

  The reference study evaluates five dyes as visibility aids for 0.2–0.3 cm tissue samples during surgical pathology preparation. Merbromin, hematoxylin, and alcian blue improved sample visibility, but hematoxylin offered the most favorable balance of visibility, safety, and compatibility with routine slide interpretation.

• G4–STAT1 Disruption and Olaparib Synergy in Cancer

  2026-08-22

  A 2026 Nucleic Acids Research study identifies the BLM promoter G-quadruplex as a regulatory platform that recruits phosphorylated STAT1 and activates BLM expression. The work further shows that berberine or coptisine can disrupt this interaction and cooperate with olaparib to increase DNA damage and colon cancer cell death, providing a mechanistic rationale for combining G4-targeting compounds with PARP inhibition.

• NF 449 and Platelet P2 Receptor Inhibition

  2026-08-22

  The reference study established NF 449 as a pharmacological tool for separating platelet P2X1 signaling from P2Y1 and P2Y12 responses. Its combination of receptor-level assays, platelet aggregation experiments, and mouse thrombosis models showed that selective P2X1 inhibition can reduce thrombus-related platelet activation without significantly prolonging bleeding time under the tested conditions.

• Fe3O4@ZIF-8 for Jaw Osteomyelitis

  2026-08-21

  The reference study develops Fe3O4@ZIF-8 core–shell nanoparticles that combine pH-responsive Zn2+ release for antibacterial action with magnetically supported bone regeneration. Its significance lies in addressing persistent infection and infected bone defects within one biomaterial platform, while also identifying bacterial membrane disruption and heat-shock-response inhibition as complementary antibacterial mechanisms.

• BMN 673 (Talazoparib) Experimental Workflow

  2026-08-20

  BMN 673 (Talazoparib) combines subnanomolar PARP1/2 inhibition with strong PARP-DNA complex trapping, making it a useful probe for DNA repair deficiency targeting. This guide translates the mechanism into practical workflows for homologous recombination-deficient models, HCC spliceosome studies, and small cell lung cancer research, with controls and troubleshooting built in.

• Age-Related CMA Decline Drives Skeletal Myopathy

  2026-08-20

  The reference study establishes chaperone-mediated autophagy (CMA) as an active regulator of skeletal muscle maintenance rather than a passive lysosomal pathway. Using reporter, genetic, proteomic, physiological, and human-tissue approaches, it connects age-related CMA loss to SERCA turnover, calcium dysregulation, muscle weakness, and progressive myopathy.

• SR 11302: AP-1 Transcription Factor Inhibitor

  2026-08-19

  SR 11302 is an AP-1 transcription factor inhibitor that suppresses AP-1 activity without activating RAR or RXR receptors. Product data support selective antiproliferative effects in several cancer cell models and reduced carcinogen-induced papilloma formation in AP-1-luciferase transgenic mice.

• Fluorinated CXCR4 Inhibitor A1 in Colorectal Cancer

  2026-08-19

  Khorramdelazad et al. evaluated A1, a fluorinated CXCR4 inhibitor, using molecular dynamics, CT-26 cell assays, and a BALB/c colorectal cancer model. A1 showed stronger computational binding, reduced tumor-cell proliferation and migration, altered immunosuppressive tumor-microenvironment features, and outperformed AMD3100 in several in vivo endpoints, while remaining a preclinical candidate requiring further validation.

• ERAD-Hijacking Chimeras for TM Protein Degradation

  2026-08-18

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule targeted protein degradation platform that recruits the ER-associated degradation pathway to eliminate transmembrane proteins. By using desonide as a SYVN1-binding warhead, the study achieved highly potent PD-L1 degradation, enhanced tumor suppression in vivo, and an initial extension to mutant HTT degradation.

• TTP–WTAP–m6A Axis in Schistosomiasis Fibrosis

  2026-08-18

  A 2026 PLOS Pathogens study identifies tristetraprolin (TTP) as an antifibrotic regulator in Schistosoma japonicum-induced liver fibrosis. Its central finding is that TTP promotes WTAP transcription through SMAD2/3, increasing m6A-dependent destabilization of TGF-β1 mRNA and limiting hepatic stellate cell activation.

• AZD0156: A Better Framework for ATM Assays

  2026-08-17

  AZD0156 is a selective ATM kinase inhibitor for studying how DNA damage signaling, repair, and checkpoint control shape cancer-cell responses. This guide adds an assay-design framework that connects target engagement with functional and translational readouts.

• Acridine Orange hydrochloride: Practical Staining Guide

  2026-08-17

  Acridine Orange hydrochloride is a cell- and organelle-permeable fluorescent nucleic acid dye for distinguishing DNA-associated green fluorescence from RNA or single-stranded nucleic acid-associated red fluorescence. It is suitable for cell cycle analysis, apoptosis detection, and flow-based nucleic acid workflows, but assay-specific settings must be validated and prepared solutions should not be stored long term.

• Phillygenin in Diabetic Nephropathy: Mechanistic Evidence

  2026-08-16

  A 2025 Phytomedicine study identifies phillygenin as a preclinical candidate for diabetic nephropathy and connects its renal protective effects with suppression of TLR4/MyD88/NF-κB signaling and restoration of PI3K/AKT/GSK3β-associated survival signaling. Its integrated podocyte, transcriptomic, biochemical, and db/db mouse experiments provide a useful framework for studying inflammation, apoptosis, and proteinuria in diabetic kidney disease.

3645 records 1/243 page Next 12345 下5页 Last page